Back to search

Article

Reducing placebo response in clinical trials of agitation in Alzheimer’s disease

2026-06-04

Abstract excerpt

High placebo response is an obstacle in developing drugs to treat agitation in Alzheimer’s disease (AAD), a prevalent and burdensome symptom. However, it has proved challenging to develop actionable models of placebo response that 1) can be applied prospectively, requiring only information available at screening or baseline, 2) yield strategies for reducing placebo response without equally depressing drug response...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
44e0df0e-2b7f-5727-a877-6182ca4190ad
DOI
10.64898/2026.06.03.26354808
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Reducing placebo response in clinical trials of agitation in Alzheimer’s diseaseDOI 10.64898/2026.06.03.26354808
Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine and Risperidone in Alzheimer’s Disease: A Real□World Cohort Study with Treatment Effect Heterogeneity AnalysisSemantic proximity
An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity
A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsSemantic proximity
Treatment effects of pharmacotherapy and non-pharmacotherapy of Alzheimer dementia: A systematic review overview and updated network meta-analysis.Semantic proximity
Association between proton pump inhibitors and dementia risk: a Mendelian randomization study.Semantic proximity
Explainable AI enables clinical trial patient selection to retrospectively improve treatment effects in schizophreniaSemantic proximity
Medication-Wide Association Study of Alzheimer’s Disease and Related Dementias: Identifying Drug Candidates from Electronic Health Records through Explainable AISemantic proximity
The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementiaSemantic proximity
Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.Semantic proximity
Distinct medical and substance use histories associate with cognitive decline in Alzheimer’s DiseaseSemantic proximity
Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer’s Disease TrialsSemantic proximity
Glucagon-like peptide-1 receptor agonist initiation and risk of clinically recorded Alzheimer's disease-type dementia in older adults with type 2 diabetes: a target trial emulation using causal machine learningSemantic proximity
Select a neighboring publication to make it the new centre.